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A B S T R A C T
Gene therapy with RNA and pDNA-based drugs is limited by poor enzymatic stability and poor cellular per-
meation. The delivery of nucleic acids, in particular by the oral route, remains a major hurdle. This review will
focus on the barriers to the oral delivery of nucleic acids and the strategies, in particular formulation strategies,
which have been developed to overcome these barriers. Due to their very low oral bioavailability, the most
obvious and most investigated biomedical applications for their oral delivery are related to the local treatment of
inflammatory bowel diseases and colorectal cancers. Preclinical data but not yet clinical studies support the
potential use of the oral route for the local delivery of formulated nucleic acid-based drugs.
1. Introduction
The improved understanding of the genetic roots of numerous dis-
eases going hand in hand with the completion of the human genome
project opened the door for the discovery of novel therapeutics speci-
fically modulating the expression of disease-relevant genes. Generally,
these therapeutics can be categorized into viral and non-viral for-
mulations. The non-viral ones offering the prospect of avoiding onco-
genic risk and of managing potentially larger payloads are either
plasmid DNA (pDNA) encoding for therapeutic proteins such as GLP-1
(Nurunnabi et al., 2017) or insulin (Rothman et al., 2005) and in case of
DNA vaccines for antigens (Sinha et al., 2017) or RNA-based drugs
including antisense oligonucleotides, short interfering RNA (siRNA;
Vaidya et al., 2019; Jain et al., 2017; Zhao et al., 2018), microRNA
(miRNA; Brown et al., 2018), messenger RNA (mRNA; Sago et al., 2018;
McKinlay et al., 2018), and Aptamer (Z. Chen et al., 2017). In contrast
to all other drugs they can edit genes curing consequently genetic de-
fects (Shim et al., 2017). Furthermore, they can be used to shut off
certain gene expression. In the case of certain gastrointestinal diseases,
such as inflammatory bowel disease (IBD) and colon cancer, where
current drug therapies are inadequate such gene-based therapeutics
may have significant clinical benefits.
Despite these convincing advantages, however, progress made over
the last decades towards a clinical use of nucleic acid-based therapeutics
is quite minor as in particular the delivery of these drugs still remains a
major hurdle. As the gastrointestinal tract (GIT) is likely the most hostile
environment in the entire body for nucleic acid-based therapeutics it may
seem brazen at first sight to focus on their oral administration. Within
this review, however, we want to convince our audience that despite all
the barriers associated with the GIT the oral administration of nucleic
acid-based drugs is not a ‘mission impossible’ and quite the contrary that
this route bears even advantages and opportunities over others.
2. Physicochemical considerations
Therapeutic nucleic acids which have been investigated in recent
years include plasmid DNA, RNA therapies such as siRNA, microRNA,
shRNA, mRNA and gene editing tools such as CRISPR. Nucleic acids
(NA) all have similar chemical structure, but differences arise in terms
of size, stability and mechanisms/site of action. These molecules, versus
traditional small drug molecules, have relatively large molecular
weights (siRNA 21–23 nucleotides, pDNA several kilobase pairs). They
are hydrophilic and negatively charged due to the phosphate backbone.
As a result of these physicochemical properties membrane permeability
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is low. In addition, the charge and size may affect diffusion through
mucus as found on the absorptive surface of the gut. These molecules
are also prone to enzymatic degradation and plasma half-lives of< 1
min (Godinho et al., 2014) have been reported. Pre-incubation of a
cyclodextrin/DNA complex in simulated intestinal fluid (SIF) con-
taining pancreatin, for instance, significantly decreased the transfection
efficacy in Caco-2 cells (O'Neill et al., 2013).
To help overcome the limitations to delivery imposed by these
physicochemical properties structural modifications have been ex-
plored. Two approaches which have been particularly successful in the
case of siRNA involve chemical conjugation of siRNA to bioactive en-
tities, and secondly the synthesis of hydrophobic siRNA derivatives.
The advantages associated with conjugates include a defined che-
mical structure, and the potential for a simpler formulation approach
which may be easier to manufacture and scale-up (Kaczmarek et al.,
2017). Direct conjugation of siRNA to a bioactive targeting ligand e.g.
GalNac for targeting hepatocytes, (www.alnylam.com) facilitates cellular
uptake and can alter the biodistribution of the nucleic acids by ensuring
cell/site specific delivery. Conjugation to lipophiles, e.g. cholesterol, can
also enhance membrane permeability relative to the unmodified NA
(Gooding et al., 2016; Malhotra et al., 2018; Wong et al., 2012). PEGy-
lation of siRNA can lead to prolonged plasma exposure and gene silen-
cing efficiency (Godinho et al., 2014), PEG conjugates may also be useful
in the gut as a stearic barrier to enzymatic degradation.
The stability, efficacy and biodistribution of hydrophobically modified
siRNA (hsiRNA) has also been extensively investigated. Alterman et al.
(2015) explained that “hsiRNA is an asymmetric compound composed of
a 15-nucleotide modified RNA duplex with a single-stranded 3′ extension
on the guide strand. Pyrimidines in the hsiRNA are modified with 2′-O-
methyl (passenger strand) or 2′-fluoro (guide strand) to enhance stability,
and the 3′ end of the passenger strand is conjugated to a hydrophobic teg-
Chol (tetraethylene glycol cholesterol) to promote membrane binding.
The single-stranded tail contains hydrophobic phosphorothioate linkages
thus promoting cellular uptake. The inclusion of phosphorothioates, ri-
bose modifications, and a cholesterol conjugate contribute to overall hy-
drophobicity and are reported to be necessary for stability and for effec-
tive cellular uptake”. These hsiRNA are non-immunogenic and have
produced gene silencing in an in vivo mouse model of Huntington's dis-
ease without any additional formulation (Didiot et al., 2016).
While the success of these approaches has to date been assessed
following parenteral administration, potential exists to explore these
technologies for oral or rectal delivery of therapeutic nucleic acids.
3. State of the art
3.1. Formulation strategies
Fig. 1 presents the various state-of-the-art drug delivery systems
evaluated for the oral administration of nucleic acid-based therapeutics.
These systems were classified in four classes: lipid-based systems, e.g.
liposomes, lipoplexes, self-emulsifying drug delivery systems (SEDDS);
polymer-based systems, e.g. chitosan, trimethylchitosan, poly-
ethylenimine (PEI), Poly Lactic-co-Glycolic Acid (PLGA); surface dec-
oration, e.g. with polyethylene glycol (PEG), antibody, galactose,
mannose; and finally, hybrid systems, e.g. nanogel, gold-PEI particles,
and Nanoparticles-in-microspheres (NiMOS).
3.1.1. Enzymatic barrier and strategies to overcome it
Having reached the intestinal fluid nucleic acid-based therapeutics
face an enzymatic barrier of nucleases. In contrast to most other gas-
trointestinal (GI)-enzymes such as proteases, where all types of en-
zymes, their activity and even recognition sites on peptides and proteins
are known (Bernkop-Schnürch, 1998), almost nothing is known about
GI-nucleases. At least we know from various studies, that nucleic acid-
based drugs are extensively degraded by GI-nucleases. Already in the
1970s it was shown that plasmid DNA is rapidly degraded when added
to just low dilutions of rat intestinal contents. This observation let the
authors of this study to conclude that the transmission of naked re-
combinant DNA in the intestinal tract is highly improbable (Maturin
and Curtiss, 1977). Results are in agreement with those of Loretz et al.
showing almost entire degradation of plasmid DNA in freshly with-
drawn and diluted porcine gastric and intestinal fluid within an hour.
The nuclease activity in the intestinal fluid was thereby determined to
correspond to 20 Kunitz mUnits of DNAse I/ml (Loretz et al., 2006). In
another study the enzymatic degradation of different antisense oligo-
nucleotides in a fasted rat small intestine homogenate model was in-
vestigated. The tested phosphodiester oligonucleotide was completely
degraded within 30min, whereas just half of a phosphorothioate oli-
gonucleotide was metabolized within 4 h demonstrating that depending
on the type of modification more or less nuclease stable nucleic acid-
based therapeutics can be designed (González Ferreiro et al., 2003).
To avoid degradation by nucleases orally administered nucleic acid-
based drugs are either chemically modified in order to make them more
resistant towards enzymes or incorporated in nanocarrier systems
shielding against enzymatic attack. Broadly speaking, chemical modifica-
tions of nucleic acids are either based on internucleotide linkage (I), nu-
cleobase (II) or sugar modifications (III). As internucleotide phosphodie-
ster linkages of DNA and RNA are the target of cleavage by endo- and
exonucleases, internucleotide linkage modifications including phosphor-
othioates, N3’ phosphoramidates, boranophosphate 2′,5′–phosphodiesters,
amide-linked phosphonoacetates, morpholinos and peptide nucleic acids
are mainly used in order to improve stability (Deleavey and Damha,
2012). This strategy is certainly first choice for synthesized nucleic acid-
based therapeutics as the effort of synthesizing a DNA- or RNA-sequence
utilizing unmodified or modified nucleotides is more or less the same.
Moreover, as synthesized nucleic acid-based drugs are comparatively small
and, in most cases, supposed to reach the systemic circulation, chemical
modifications are also helpful to reduce the systemic metabolism and
consequently to prolong elimination half-life. For nucleic acid-based
therapeutics that cannot be sufficiently stabilized by modifications or that
are simply too big to be chemically modified such as plasmids, however,
this strategy does not lead to the desired result. For this type of nucleic
acid-based drugs protection towards nucleases can only be achieved by
carrier systems shielding on the one hand the incorporated drug towards
nucleases and delivering on the other hand their payload at least to the
apical membrane of enterocytes or even beyond where the drug cannot be
degraded anymore by nucleases of the intestinal fluid. In order to avoid
free access of nucleases to nucleic acid-based therapeutics they can be co-
precipitated with cationic polymers such as polyethyleneimine (Banerjee
et al., 2006), chitosan (Ragelle et al., 2014), thiolated chitosans (Zhang
et al., 2013) or dendrimers (Bielinska et al., 1997). Utilizing this tech-
nique, nanoparticles can be simply generated providing at least to a cer-
tain extent a protective effect. Alternatively, nucleic acid-based ther-
apeutics can be complexed with cationic surfactants such as DOPA or
DOTA also forming nanoparticles. The protective effect towards nucleases,
however, seems to be considerably low. Hauptstein et al. (2015), for in-
stance, showed a rapid degradation of pDNA although complexed with
Lipofectin. Utilizing liposomes is another approach. Because of their hy-
drophilic character, nucleic acid-based drugs assemble not just on the
inner phospholipid bilayers, where they maybe protected, but also on the
outer bilayer where they are not at all protected from nucleases. Due to the
addition of cationic lipids, however, nucleic acid-based drugs are coated
by a lipophilic shell likely assembling in lipophilic regions of liposomes
where they are to a high extend protected towards nucleases (Cortesi et al.,
1996). A potentially efficient strategy to provide protection towards nu-
cleases is the use of SEDDS. Due to a hydrophobic ion pairing (HIP) with
cationic surfactants nucleic acid-based drugs can be efficiently in-
corporated in SEDDS pre-concentrates. As nucleases are very hydrophilic,
they cannot penetrate into the oily droplets formed in the intestinal fluid.
A comparision of the protective effect of cationic lipid complexes with that
of SEDDS as illustrated in Fig. 2 demonstrates the potential of this strategy
(Hauptstein et al., 2015).
C.M. O'Driscoll, et al. European Journal of Pharmaceutical Sciences 133 (2019) 190–204
191
Another strategy is making use of nuclease inhibitors that are co-
administered with the nucleic acid-based therapeutic in order to sup-
press the activity of these enzymes during the drug liberation and ab-
sorption process. So far, however, very little is known about potent
inhibitors of intestinal nucleases. At least EDTA, sodium dodecyl sulfate
and aurintricarboxylic acid were proven to exhibit a pronounced in-
hibitory effect (Loretz et al., 2006). In order to avoid a rapid dilution
and absorption of these inhibitors in the intestine leaving the com-
paratively poorly absorbed therapeutic agent unprotected behind in the
intestinal lumen, these inhibitors can be immobilized on not absorbable
polymers functioning as drug carrier matrix. An example for such sys-
tems is chitosan-EDTA conjugate (Loretz et al., 2006). If just a very few
drug administrations are needed to achieve the therapeutic aim such as
in case of DNA vaccines, the strategy seems promising. In case of long-
term treatments, however, side effects will likely be a hindrance. At
least we know from orally administered protease inhibitors that the
body compensates the suppressed enzymatic activity in the intestine via
a feedback regulation loop resulting not just in an increased secretion of
degrading enzymes but for instance in case of serine proteases also in a
hypertrophy and hyperplasia of the pancreas e.g. (Otsuki et al., 1987).
Taken all, whenever chemical modifications on therapeutic nucleic
acids are feasible in order to provide stability towards nucleases, it is
preferred over all other strategies. Unless, nanocarrier systems are
likely the most promising alternative.
3.1.2. Mucus barrier and strategies to overcome it
Having overcome this enzymatic barrier nucleic acid-based ther-
apeutics are confronted with another huge barrier namely the mucus
gel layer. Mucus glycoproteins designated mucins exhibit cysteine-rich
subdomains that are crosslinked with each other via disulphide bonds.
They built up a three-dimensional network with a mesh size of
~10–200 nm within its microstructure that blocks most pathogens and
xenobiotics too large to permeate it. In contrast to the microstructure of
mucus with a defined mesh size, its macrostructure is more hetero-
geneous. Because of this heterogenicity and considering that the mucus
is not a static but a very dynamic system, the network is even for an
invader larger than 200 nm to some extent leaky. Furthermore, the
region of Payer's patches is less covered by a mucus layer. This slight
leakiness of the mucus layer, however, is in most cases insufficient for
an efficient nucleic acid-based drug delivery, apart from this size de-
pendent barrier large hydrophilic molecules are trapped in the mucus
by its adhesive nature. Due to the formation of numerous non-covalent
bonds such as ionic interactions, hydrogen bonds and van-der-Waals
forces they are immobilized within the mucus (Bernkop-Schnürch and
Fragner, 1996). Taking its adhesive nature, the thickness of the mucus
layer in the small intestine of up to 400 μm and an estimated mucus
turnover in the range of 1–4.5 h (Lehr et al., 1991) into account, the
mucus layer is for small nucleic acid-based therapeutics at least a hin-
drance and for pDNA it is an almost impermeable barrier. As in case of
an oral gene therapy of gut related diseases such as cystic fibrosis (Ooi
and Durie, 2016) or lactose intolerance (During et al., 1998) intestinal
stem cells being in the crypts of Lieberkühn have to be reached, the
mucus barrier becomes even more challenging. Although there is a
constant water flow towards the intestinal epithelium accelerating the
diffusion process of drugs through the mucus gel layer (Fabiano et al.,
2017), it is obvious that without the aid of mucolytic agents and/or
Fig. 1. State-of-the-art drug delivery systems for oral administration of nucleic acid-based therapeutics.
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appropriate drug carriers' nucleic acid-based therapeutics are losing
potential because of the mucus gel barrier.
In order to permeate the mucus gel layer in high quantities the drug
delivery system has to be small enough – preferably< 100 nm – and
has to be mucoinert. Nanoparticles formed of nucleic acid-based ther-
apeutics and cationic polymers exhibiting in combination a negative
zeta potential seem to fulfill these demands. They can be generated
with a mean size below 100 nm. Moreover, combining anionic and
cationic polymers in these particles results in a high density of anionic
and cationic charges on the particle surface making them comparatively
slippery. They imitate actually viruses that can easily move across the
mucus layer exhibiting also a high density of anionic and cationic
charges on their surface (Pereira de Sousa et al., 2015). Nevertheless,
such systems as well as liposomes exhibit still lower mucus permeating
properties than SEDDS. PEG coatings on nanoparticles have been uti-
lized for overcoming various biological barriers to efficient gene de-
livery, in particular to promote mucus penetration (Suk et al., 2016). As
most SEDDS contain PEGylated surfactants in order to guarantee self-
emulsification, their comparatively high mucus permeating properties
can be explained by PEG substructures assembling on the surface of the
oily droplets making them highly mucoinert (Griesser et al., 2018).
Although PEGs are certainly helpful in order to overcome the mucus
barrier, they are disadvantageous for the particle uptake by epithelial
cells. Ball et al. (2018), for instance, observed a decreased efficacy of
orally administered siRNA nanoparticles the more PEG they added to
these nanocarriers. Because of this PEG dilemma nanocarriers of high
density of anionic and cationic charges on their surface are the pre-
ferred strategy in order to provide mucoinert properties.
Other strategies are utilizing mucolytic agents such as sulfhydryl
compounds cleaving disulfide bonds within the mucus gel layer.
Sandberg et al., for instance, could remove mucus both with dithio-
threitol and N-acetyl-cysteine between the villi but failed to reach the
crypt lumen. In addition, as explained by Sandberg et al. (1994), to en-
hance mucus release from the crypt lumen, they chose “pilocarpine due
to its cholinergic properties and preferential binding to muscarinic re-
ceptors on crypt goblet cells. Pilocarpine given intraperitoneally 30 min
prior to the mucolytic wash resulted in significant eradication of mucus
down into the crypt lumen”. Furthermore, mucolytic enzymes such as
papain or bromelain cleaving certain protein substructures within the
mucus gel layer might be another option (Müller et al., 2013). As such
mucolytic enzymes do not cleave nucleic acids at all and they make the
absorption membrane to some extent more accessible for drug uptake by
cleaving tight junctions (Bock et al., 1998), they are among mucolytic
agents first choice. In particular the combination of such enzymes with
nanocarriers exhibiting a high density of anionic and cationic charges as
described above might be a straight forward approach.
3.1.3. Membrane barrier and strategies to overcome it
The epithelium lining of the GI-tract portrays another and the likely
most challenging barrier to orally administered nucleic acid-based
drugs. Brush border microvilli present a variety of charged molecular
species, including polar carbohydrates and charged amino acid side
chains, thus providing a high-density negative charge on the microvilli
at the enterocytes' apical surface (Bennett et al., 2014). Due to this
anionic charge, it is primarily a challenge for nucleic acids to reach and
be attached to the cell membrane. Even if they overcome this repulsion
effect, the situation does not take a turn for the better. Because of their
hydrophilic macromolecular nature, they are unable to permeate the
lipophilic phospholipid bilayer of enterocytes. For nucleic acid-based
therapeutics exhibiting a molecular mass< 5 kDa the paracellular
route of uptake seems to be an option, whereas for drugs above that size
there seems to be no escape. The likely most important way to over-
come the cell membrane is via endocytosis. Nucleic acid-based ther-
apeutics internalized via endocytosis, however, are delivered via the
early endosomes to lysosomes for degradation (Luzio et al., 2007), to
the trans-Golgi network for processing (Gu et al., 2001), or recycled
back to the membrane (Maxfield and McGraw, 2004). For RNA the
cytosol is already the target site, whereas pDNA still has to reach the
nucleus. Although antisense oligonucleotides function in both the cy-
toplasm and nucleus, localization to different subcellular regions can
affect their therapeutic potency (Crooke et al., 2017). In case of sys-
temic delivery nucleic acid-based drugs have to permeate also the
Fig. 2. Results of enzymatic degradation studies with DNase I. Reaction was
stopped after predetermined time points and extent of degradation was visua-
lized by agarose gel electrophorese. Gel was prestained with GelRED® and
detected under UV light. Gel shows results for a 1% naked pDNA solution, 1%
resuspended pDNA–Lipofectin® complex and 1% nanoemulsion of
pDNA–Lipopfectin® complex loaded SEDDS.
Adopted from Hauptstein et al. (2015).
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plasma membrane in order to reach the systemic circulation. In Fig. 3
the different barriers and routes of uptake are illustrated.
For small nucleic acid-based drugs that are supposed to reach the
systemic circulation, permeation enhancers either making the cell
membrane leakier or opening up tight junctions have already shown
potential in various studies. Raoof et al. (2004), for instance, could
achieve an oral bioavailability of 1.4% for an antisense oligonucleotide
in dogs when the drug was co-administered with a medium chain fatty
acid. Results of this study are illustrated in Fig. 4. An overview about
permeation enhancers for oral administration is provided by numerous
reviews e.g. (Maher et al., 2016). In order to improve membrane per-
meability of entire nanocarrier systems, however, mostly other strate-
gies seem to be more efficient. These strategies are mainly focusing on
lipophilic (I), cationic (II) and cell penetrating peptide decorated na-
nocarriers (III).
Since the development of transfection by lipids - designated lipofec-
tion (Felgner et al., 1987) - lipoplexes formed between nucleic acid-based
therapeutics and cationic lipids are the likely most commonly used
strategy to overcome the membrane barrier. Due to the addition of ca-
tionic lipids the anionic charges of nucleic acid-based drugs are neu-
tralized and in parallel the lipophilic character is strongly raised. Fusion
of these lipophilic complexes with the membrane is consequently fa-
cilitated. Cell uptake studies of lipoplexes containing a fluorescent
plasmid revealed a very efficient uptake of even 100% and a mechanism
that could be different from endocytosis. The escape of the plasmid from
intracellular vesicles and the traffic from the cytoplasm to the nucleus,
however, were identified as the limiting steps of this approach (Escriou
et al., 1998). As lipoplexes are poorly soluble in GI-fluids, the problem of
poor membrane permeability seems just to be shifted to a problem of
poor solubility. In other words, class 3 drugs are transformed to class 2
drugs without any real improvement in oral bioavailability. According to
these considerations lipoplexes cannot be regarded as stand alone
strategy. They need to be combined with other strategies providing suf-
ficient solubility and carrying them over the unstirred water layer to the
absorption membrane. Lipophilic carrier systems such as SEDDS might
fulfill this task. Alternatively, lipophilic nanoparticles can also enter the
systemic circulation via the lymphatic route (Murakami et al., 2015).
Cationic nanocarriers are also often used to facilitate nucleic acid-
based drug penetration of cells as they interact with the anionic pro-
teoglycans of the cell membrane, depolarize it and induce endocytosis
(Poon and Gariépy, 2007; Zhang et al., 2007). The concept seems to
work quite efficiently as long as there is no mucus gel layer involved.
When these cationic carriers, however, have to permeate the anionic
charged mucus layer, they either stick in the mucus or are destabilized
due to extensive ionic interactions or they reach the cell membrane
having been coated with an anionic layer of mucus neutralizing their
cationic charge. Parenterally administered cationic nanocarriers are
facing similar problems with anionic serum proteins resulting in the
formation of undesirable aggregations or premature release of nucleic
acid-based therapeutics. This so-called ‘polycation dilemma’ (Wang
et al., 2012; Bernkop-Schnürch, 2018) has recently been addressed by
zeta potential changing carrier systems. Due to an enzymatic cleavage
of phosphate substructures from the surface of these drug carrier sys-
tems by the membrane bound enzyme intestinal alkaline phosphatase,
they change the zeta potential from negative to positive right after
Fig. 3. Physiological barriers in the gastrointestinal tract for nucleic acid-based therapeutics after oral dosing.
Fig. 4. Mean plasma concentration–time profiles at days 1, 2, and 6 following
oral administration of enteric coated tablets containing 80mg of an antisense
oligonucleotide and sodium caprate as permeation enhancer in dogs.
Adopted from Raoof et al. (2004).
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having permeated the mucus gel layer and having reached the mem-
brane (Bonengel et al., 2016).
As most cell penetrating peptides (CPPs) are arginine- and/or lysine-
rich peptides exhibiting a cationic charge their effect is often a com-
bination of intrinsic cell penetrating properties and their cationic
character. Recently, Mahmood et al. could show an almost 3-fold im-
proved cellular uptake of SEDDS due to the addition of a HIV-1 Tat
peptide-oleoyl conjugate. The transfection efficacy of this system was
almost twice as high as that achieved with lipofectin (Mahmood et al.,
2016). In another study, for instance, peptide vectors containing a la-
minin receptor-targeting sequence were utilized showing an even 7
times higher transfection efficacy than that of Lipo 2000 (Meng et al.,
2018). Although these comparisons with other systems have to be seen
with caution, CPPs seem to have potential for oral nucleic acid-based
drug delivery. The technology, however, is certainly limited by the
degradation of CPPs by proteases and peptidases in the GI-tract. This
degradation by gastrointestinal peptidases, however, can be avoided by
the use of D-configured instead of L-configured amino acids, as CPPs
consisting of D-configured amino acids are on the one hand not cleaved
anymore by proteolytic enzymes but on the other hand still recognized
by their target site on the cell membrane. Utilizing poly-D-arginine
instead of poly-L-arginine is good example for this approach.
Furthermore, the fact that CPP cationic charges are neutralized by
the negatively charged mucus substantially compromise their inter-
nalization capabilities. Recently, this problem was solved by the cova-
lent attachment of anionic phosphoserine substructures on the top of
CPPs heading out of nanocarriers providing an anionic charge on the
surface. On the cell membrane these anionic phosphoserine sub-
structures are cleaved off by alkaline phosphatase. Although the con-
cept was used for oral insulin delivery showing a 1.9-fold improved
systemic uptake of this therapeutic peptide vs. the same formulation
without the phosphoserine substructures, the study provides at least
evidence for the potential of this strategy for oral hydrophilic macro-
molecular drug delivery in general (Wu et al., 2018). The combination
of complementary strategies is of course helpful for the design of more
efficient oral nucleic acid delivery systems.
3.2. Local versus systemic delivery
Local delivery to the intestine can be achieved via endoscopy
techniques, by oral administration where passage through the stomach
is an additional barrier, or by rectal administration which avoids the
hostile environment of the upper small intestine. Local therapeutic ef-
fects on the intestine have also been reported following systemic ad-
ministration (Peer et al., 2008).
Oral delivery of therapeutic nucleic acid-based therapeutics has
many advantages versus systemic administration including; con-
venience for the patient and thus increased compliance; the potential to
treat diseases of the GIT including IBD (Crohn's disease and Colitis) and
cancer; and the avoidance of challenges which exist in the blood in-
cluding interactions with plasma proteins, aggregation and opsonisa-
tion. However oral delivery is not a trival matter and major challenges
both physicochemical and physiological exist (as described in Section
2). While progress has been made through innovative formulation
strategies (Section 3.1) to date clinical translation of oral products has
not been realised.
The design of site-specific delivery systems which would restrict
release of the nucleic acids to the disease location would be advanta-
geous, for example in the case of IBD and colon cancer which occur in
particular areas of the gut and which are often patient specific. Several
formulation approaches, including the use of pH-dependent and
bioadhesive polymers, have already been investigated and widely re-
viewed for intestinal site-specific drug delivery, some of these strategies
could be applied to the delivery of nucleic acid-based therapeutics.
3.2.1. Inflammatory bowel disease
However, if targeting to the disease site is the aim e.g. in IBD then
the physiological changes present in the GIT due to the disease, in-
cluding pH, transit time, mucous production and the microbiome,
which can influence the performance of the delivery system must be
taken into consideration (Guo et al., 2016; Hua et al., 2015). The pH in
the colon of UC patients is reported to be from 2.3 to 5.5 relative to the
healthy colon where the pH range is higher, 6.8 to 7.2 (Hua et al.,
2015). Negative effects on delivery can result from the symptoms of the
disease including diarrhea which may increase transit times. In con-
trast, disease related mucosal tissue damage may aid uptake by target
cells such as enterocytes and macrophages.
In addition, disease-induced changes in the expression of receptors,
adhesion molecules and cell surface proteins have also been reported
(Guo et al., 2016; Hua et al., 2015). Several receptors overexpressed in
IBD have been investigated for drug delivery using ligand targeted NPs.
Active targeting in IBD: Polystyrene nanoparticles tagged with anti-
ICAM-1 antibodies were administered orally to wild type mice C57BL/6.
The intercellular adhesion molecule (ICAM-1) is expressed on the surface
of GI cells and is upregulated in diseases such as IBD (Mane and Muro,
2012). While up to 60% of antibody was degraded receptor mediated
endocytosis in duodenal tissue was demonstrated implying that with
further formulation development this receptor may be worth pursuing.
Targeting receptors (mannose and galactose-type lectin) on macro-
phages, known to be involved in gut inflammation, has also been in-
vestigated as a means of enhancing oral delivery of siRNA (Table 1).
Mannosylated nanoparticles formulated using a cationic polymer and
containing TNF alpha siRNA were effectively taken up in vitro by mac-
rophages and inhibited protein expression in colitis tissue ex vivo (Xiao
et al., 2013). Oral administration of galactosylated trimethyl chitosan-
cysteine nanoparticles loaded with Map4k4 siRNA decreased the severity
of inflammation in a DDS colitis mouse model (Zhang et al., 2013).
Nanoparticles made using poly (lactic acid) poly (ethylene glycol)
block copolymer (PLA–PEG) containing TNF alpha siRNA and grafted
with a Fab′ portion of the F4/80 Ab (Fab′-bearing) were taken up by
macrophages and following oral administration of a hydrogel con-
taining the targeted NPs the symptoms of colitis were attenuated
(Laroui et al., 2014). Another target for nanoparticles design is CD98, a
type II transmembrane protein overexpressed in gut inflammation (Xiao
et al., 2014). Nanoparticles tagged with a surface antibody against
CD98 containing CD98 siRNA [CD98 antibody (scCD98)-PEG-urocanic
acid-modified chitosan (scCD98-PEG-UAC)/PEI (2 kDa)/siCD98] were
administered orally embedded in a chitosan/alginate hydrogel. Ap-
proximately 24% of macrophages were seen to take up the nano-
particles resulting in a significant decrease in the severity of the colitis.
In addition to the SEDDS described above (Section 3.1), a range of
novel formulation approaches has also been explored for intestinal
delivery of nucleic acids. NiMOS have been extensively investigated for
oral delivery of pDNA/siRNA mainly for the treatment of IBD
(Attarwala et al., 2018; Bhavsar and Amiji, 2007; Kriegel and Amiji,
2011). This formulation has shown promising gene transfection and
gene silencing in a dextran sulphate induced colitis mouse model re-
sulting in alleviation of disease symptoms.
Nanoparticles fabricated from Beta 1, 3-D-glucan (from bakers'
yeast), GeRPs, encapsulating Map4k4 siRNA (20 μg/kg) were designed
to be taken up by macrophages in the GALT. Following oral gavage,
GeRPs inhibit LPS-induced TNF-alpha production in serum and peri-
toneum (Aouadi et al., 2009).
Amphiphilic polyallylamine-base polymeric micelles formed nano-
complexes (150–300 nm) with siRNA (Guo et al., 2013). The resulting
complexes were stable in simulated gastric/intestinal fluids achieving
cellular uptake, endosomal release and gene knockdown in a Caco-2
cell model.
Bio-responsive formulations have also been designed to achieve oral
delivery of therapeutic NAs. Thioketal NPs were formulated using a
novel polymer poly-(1,4-phenyleneacetone dimethylene thioketal)
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(PPADT) that degrades selectively in response to elevated reactive
oxygen species (ROS) at inflamed sites in IBD (Wilson et al., 2010). Oral
administration of the TNF-alpha siRNA loaded NPs to a mouse UC
model resulted in localised delivery to the colon, reduced cytokine le-
vels resulting from gene silencing and alleviation of the disease partly
due to the enhanced stability of the NPs in the GI tract.
A TNF-alpha siRNA loaded nanogel encapsulated in a P(MAA-co-
NVP) polymer protected the nanogel from release in the gastric acidic
pH. At the higher intestinal pH of 6–7.5 the polymer swells facilitating
enzymatic degradation of the polymer matrix and release of the nanogel
for cellular uptake. The enzyme and pH-responsive formulation
achieved cellular uptake in murine macrophages resulting in knock-
down of TNF-alpha (Knipe et al., 2016).
3.2.2. Colon cancer
Another obvious disease target for oral delivery of nucleic acid-based
therapeutics is colon cancer. Here again local delivery and uptake into
the tumour is desirable and active targeting using a receptor ligand ap-
proach is an attractive possibility. A variety of tumour targeting ligands
has been identified (Riaz et al., 2018) and specific examples including a
12-residue peptide that interacts with integrin alpha6beta1 over-
expressed on colon cancer cells has shown promise (Ren et al., 2016).
Mutations of the adenomatous polyposis coli (APC) gene are frequently
associated with the development of colorectal cancer. Gene replacement
therapy has shown promise in animal models of the disease. Following
oral administration of a lipofectamine-based liposomal formulation con-
taining a functional APC gene to APCmin mice a 54% reduction in in-
testinal polps was detected (Lew et al., 2002). Nanoparticles formulated
with galactose modified trimethyl chitosan-cysteine conjugate were used
to co-deliver survivan shRNA-expression pDNA and vascular endothelial
growth factor siRNA via oral administration (Han et al., 2014). The tu-
mour animal model was established following subcutaneous injection of
hepatoma H-22 ascites or BEL-7402 cells. Following oral administration,
the NPs penetrated the gut wall, attributed to mucoadhesion and opening
of TJs, and accumulated in the tumour tissue. The co-delivery of shRNA
and siRNA (daily for 20 days, 1mg pDNA/kg and 200 μg siRNA/kg)
mediated a synergistic therapeutic response, resulting in silencing the
expression of both survivan and VEGF and significant tumour regression
which varied with ligand grafting density.
The same group (Yin and colleagues) synthesized a modified chit-
osan with histidine and cysteine amino acids (Zheng et al., 2015). This
vector was used to deliver survivan shRNA in a SC xenograft hepatoma
tumour mouse model. The vector was designed to overcome the bar-
riers to delivery at the cellular level including, cellular uptake, en-
dosomal escape (histidine), increased nuclear localisation and glu-
tathione mediated release (cysteine). Following oral administration (20
μg shSur-pDNA per mouse per day for 18 days), tumour growth was
retarded and surviving was extended due to increased apoptosis.
Oral delivery of siRNA has also been investigated to treat colorectal
liver metastases (CLM) formed from colorectal cancer (Kang et al., 2017).
This study describes the formulation of gold (Au). siRNA nanoparticles
coated with glycol chitosan and targeted with taurocholic acid (TCA).
The TCA was selected to protect the siRNA from gastrointestinal de-
gradation and ensure targeting to the CLM via enterohepatic circulation.
The Akt siRNA initiates apoptosis and the efficacy was evaluated by
monitoring expression of the apoptosis markers; Bax, caspase-9 and
PARP. Detailed mechanistic studies illustrated vesicular mediated (re-
ceptor mediated transcytosis) uptake of the TCA targeted nanoparticles
from the ileum, transport from the ileum to the liver was confirmed by
identification of the nanoparticles in the hepatocytes. The presence of the
nanoparticles in the kidneys suggests elimination by the kidneys. Fol-
lowing oral administration (siRNA 25 or 100 μg/kg) using an orthotopic
CLM animal model (established by injection of CT26 cells into the
spleen), the therapeutic efficacy of the targeted nanoparticles was sig-
nificantly greater versus the untargeted Au-chitosan nanoparticle. The
TCA targeted nanoparticles produced a 43–58% greater reduction in theTa
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number of tumour nodules via induction of cell apoptosis by regulating
the Akt/PI3K pathway.
Enterohepatic recycling via the bile acid pathway has also been
exploited for oral delivery of GLP-1 pDNA complexed with PEI and
coated with heparin-taurocholic acid (Nurunnabi et al., 2017). Ther-
apeutic efficacy was confirmed in a genetically engineered T2DM Zucker
diabetic fatty rat model where normal blood glucose level was sustained
following oral administration of the TCA targeted GLP-1 nanoparticle.
3.2.3. Microbiome
One approach to trigger the release in the colon which has attracted
recent attention is based on exploiting the microbiome. There has been
an explosion of interest detailing the role of the microbiome as a de-
terminant of the health status of the human host and in the develop-
ment of new biotherapeutics (Gibson et al., 2017; Prakash et al., 2011;
Serban, 2014). Recent studies have illustrated that the gut microbiota in
IBD patients is altered versus healthy gut (Nishida et al., 2018; Sheehan
and Shanahan, 2017). This provides opportunities to exploit ‘micro-
biome triggered’ site specific drug delivery by utilizing materials,
mainly polysaccharides, selectively metabolized by the unique IBD
microbiota (Jain et al., 2014; McConnell et al., 2008). Matching the
delivery technology to the microbiota may enable targeting of nucleic
acids to the colon for treatment of diseases including IBD and cancer.
3.3. ADMET
3.3.1. Pharmacokinetics and biodistribution
Typically following IV administration siRNA it is rapidly eliminated
and displays a short half-life ranging from seconds to minutes (Evans
et al., 2016; Godinho et al., 2014; O'Neill et al., 2013). Circulation time
can be extended by complex formation with for example cationic vec-
tors and by PEGylation (Kolate et al., 2014; Miteva et al., 2015). The
reasons for the short half life of siRNA and some of the cationic for-
mulations include; enzymatic degradation by RNase, interaction with
serum proteins causing siRNA release or nanoparticle aggregation and
opsonisation (Park et al., 2016). For oral administration some of these
issues, such as interactions with plasma proteins and the toxicity of
cationic materials, may not be problematic. In contrast, other barriers
arise such as the need to resolve passage through the stomach, de-
gradation by the digestive enzymes, mucus and poor membrane per-
meability, as discussed in Section 2 above.
Limited PK data has been published following oral administration of
nucleic acids. Han et al. (2014) monitored distribution into plasma fol-
lowing oral administration of 20μg FTTC-pDNA and 4μg TAMRA-siRNA
formulated in a multifunctionalised chitosan-based vector. The nano-
particles increased the percentage distribution in plasma by approxi-
mately 7-fold relative to naked siRNA with maximum amounts detected
at around 6 hour post administration, similar results were reported with
the pDNA. Simultaneously, the percentage distribution in the intestine
decreased rapidly over the first 6 h while values in the tumour increased
reaching a maximum at around 11 hour post administration.
Direct northern and quantitative polymerase chain reaction (PCR)
were used to detect the disposition of siRNA.chitosan nanoparticles
(Ballarín-González et al., 2013). In contrast to oral dosing of naked
siRNA (78 μg per mouse) the chitosan nanoparticles maintained the
stability of the siRNA and were detected in the stomach, proximal and
distal small intestine, and in the colon as early as 1-hour post dosing
and persisted for up to 5 h. Biodistribution studies, 1-hour post dosing,
also indicated intact siRNA in the liver, spleen and kidney although the
levels varied depending on the N:P ratio of the nanoparticles.
Trimethyl chitosan cysteine nanoparticles containing TNA-alpha
siRNA were modified by mannose to target macrophages following oral
delivery (50 μg/kg) (He et al., 2015). Absorption occurred via en-
terocytes and Peyers patches resulting in reduced systemic production
(serum) of TNF-alpha. Distribution to macrophage-enriched re-
ticuloendothelial tissues including liver, spleen and lung resulted in
decreased tissue levels of TNF-alpha mRNA in an acute hepatic injury
rat model thus protecting the animals from further hepatic damage.
Kang et al. (2017) also looked at the biodistribution of the gold
(Au). siRNA nanoparticles coated with glycol chitosan and targeted
with taurocholic acid (TCA) for the treatment of colorectal liver me-
tastases (CLM). Using a fluorescent marker, results indicated that, re-
lative to the untargeted nanoparticles, the levels of the targeted for-
mulation were 1.2 to 1.4-fold greater in the ileal and liver at 6 and 12 h
respectively. A more detailed biodistribution study over 48 h confirmed
the higher levels in the liver with the TCA targeted nanoparticles in-
dicating the successful exploitation of the enterohepatic circulation
mechanism for targeting to the CLM.
Uptake by the bile acid transporter in the ileum and transport to the
liver following oral administration of taurocholic acid targeted nano-
particle (HTCA) containing GLP-1 pDNA was also confirmed by bio-
distribution studies (Nurunnabi et al., 2017). High levels of the HTCA
nanoparticles were detected in the ileum and liver 3 hour post oral
administration. Comparative distribution studies indicated that the
nontargeted formulations remained stuck in the GIT, in contrast the
HTCA nanoparticles survived the gut environment were absorbed from
the ileum and were detected in the liver.
Using a lipid-based NP (LNP) containing siRNA Ball et al. (2018)
investigated the distribution of fluorescently labelled naked siRNA and
LNPs in the intestine over 8 h after oral administration. By 30min both
the naked siRNA and the LNP had travelled through the stomach and
arrived in the small intestine. Over 8 h the fluorescent signal in the colon
increased while the overall signal decreased with time indicating elim-
ination from the gut. No fluorescence was detected in the kidneys, heart,
liver, spleen or pancreas suggesting that neither the siRNA nor the LNPs
crossed the intestinal membrane into the blood. Although the LNPs ar-
rived in the intestine no gene silencing was detected after 24 h in the gut
samples taken possibly due to an insufficient dose (5mg/kg siGAPDH).
In summary, the in vivo studies reviewed above show that orally
administered nanoparticles containing nucleic acid distribute to various
locations along the GIT including the colon and achieve cellular uptake
thus facilitating local therapeutic effects. Formulations may need to be
modified to ensure maximum retention locally in the GIT to avoid un-
wanted systemic effects. In some cases, systemic absorption has been
reported with distribution mainly to the liver this is useful where
treatment of liver disease is required.
4. Pre-clinical models
A wide range of models have been developed over the years to assess
intestinal delivery mainly with traditional low molecular weight drugs in
mind. Many of these models can equally be applied to assess intestinal
delivery of macromolecules (Harloff-Helleberg et al., 2017). While
models simulating the healthy gut can provide useful information the
physiological environment may be altered significantly by disease (e.g.
IBD, cancer) and this should be taken into consideration as the resulting
changes will likely impact on the performance of the delivery system
(Hua et al., 2015). Data using such models have previously been discussed
in Section 3 above. The physiological barriers to non-viral intestinal de-
livery of gene therapeutics and the pre-clinical models used to assess
delivery in disease conditions has previously been reviewed (O'Neill et al.,
2011b) consequently this review will focus on more recent developments.
4.1. In vitro models
4.1.1. Models of the extracellular GIT environment
A range of biorelevant media have been developed to reflect the
varying luminal conditions of the GIT in the fed and fasted states. These
media reflect differences in pH, buffer capacity, the presence of bile salt
and enzymes in the various parts of the GIT, stomach, small and large
intestine (Markopoulos et al., 2015; Singh et al., 2015). While such
media were initially designed to assess drug dissolution, they have been
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utilized to quantify the intestinal stability of nucleic acids in non-viral
delivery formulations (Guo et al., 2013; McCarthy et al., 2013; O'Neill
et al., 2013). More recently biorelevant media designed to reflect in-
testinal disease states have been proposed (Effinger et al., 2018b).
Changes in hydrodynamics, luminal contents and microbiota in a
healthy gut were compared to those reported for patients suffering from
ulcerative colitis, Crohn's disease, coeliac disease, irritable bowel and
short bowel syndromes. This bank of information will inform the design
of disease-specific biorelevant media which could be used to study gene
therapeutics engineered to target particular intestinal diseases (Effinger
et al., 2018a, 2018c).
The presence of a mucus layer on the surface of the intestinal
membrane may represent a diffusional barrier to gene therapy (Duncan
et al., 2016) and various technological strategies have been explored to
overcome this barrier (as discussed above in section 3.1.2.) (das Neves
and Sarmento, 2018). A wide variety of methods to investigate the
diffusion of drugs and particles in mucus has recently been reviewed
including the use of in vitro isolated mucus models (Lock et al., 2018).
The source of mucus (native versus commercial), the collection, pre-
paration, characterization and storage of samples may influence results
produced and consequently all need to be carefully controlled. Ex-
perimental techniques used to explore the barrier functions of mucus
include multiple particle tracking (MPT) (Lai et al., 2007), fluorescent
recovery after photobleaching (FRAP) (Yildiz et al., 2015), penetration
studies and bulk diffusional studies (Groo et al., 2013). While valuable
information can be obtained via techniques such as MPT and FRAP
specialised equipment and trained personnel are required and therefore
they may not be conducive to routine screening. In contrast to MPT
which facilitates the study of single particle dynamics, simpler techni-
ques utilizing capillary tubes (Popov et al., 2016) or membranes are
used to investigate bulk particle transport (Groo et al., 2013; Groo et al.,
2014).
4.1.2. Cell culture models
A range of intestinal cell culture models have been used to assess
intestinal delivery of gene therapeutics (O'Neill et al., 2011b). The
CaCo-2 model has been used to quantify the extent of cellular uptake,
the degree of transfection and intracellular trafficking of non-viral gene
delivery vectors (Cryan and O'Driscoll, 2003; O'Neill et al., 2011a). The
influence of mucus, which may be altered in disease conditions thus
influencing uptake, as a diffusional barrier to gene therapeutics has
been investigated using co-culture models of Caco-2 and mucus se-
creting cells such as Ht29GlucH (Cryan and O'Driscoll, 2003; O'Neill
et al., 2013). If particulate uptake via M-cells is the aim, models in-
corporating M-Cells in an intestinal follicle-associated epithelium (FAE)
may be useful (Wilson et al., 2010). M cells significantly influenced the
uptake and localisation of pDNA-loaded chitosan and trimethylchitosan
nanoparticles (Plapied et al., 2010).
Cell models representative of the disease of interest may provide
more useful information (Guo et al., 2016). In the case of IBD a variety
of cell models incorporating macrophages such as RAW264.7 has been
used, which when stimulated with LPS secrete elevated levels of cyto-
kines characteristic of IBD (McCarthy et al., 2013). The formation of a
co-culture incorporating macrophages, Caco-2, Ht29 or FAE cells to
form a more physiologically relevant model may also be possible
(O'Neill et al., 2011b).
More recently interest has grown in the potential to create 3D cell-
based models to help simulate more accurately the in vivo environment
(Fitzgerald et al., 2015). It has been shown that cells grown in a 3D
architecture behave differently to those grown in 2D likely due to the
intimate cell-cell contact and the resulting cross-talk. Three dimen-
sional models of the intestine using collagen (Yu et al., 2012) and hy-
drogel (Dosh et al., 2017) scaffolds have produced drug permeability
values reflective of in vivo data. To replicate the topography of the
intestine cross-linked collagen hydrogel was molded into crypt and
villi-like structures. Human small intestinal cells were shown to
proliferate on these scaffolds and underwent differentiation in response
to chemical stimuli thus creating a model which replicates the anato-
mical shape of the human small intestine (Wang et al., 2017). Using a
triple co-culture model of intestinal myofibroblasts (CCD18-Co cells)
embedded in Matrigel, onto which epithelial enterocytes (Caco-2 cells)
and mucus-producing cells (HT29-MTX cells) were seeded, Pereira et al.
(2015), showed that the CCD18-Co cells secreted fibronectin which
acted as a type of ECM supporting the cells in a 3D architecture. This
mucus secreting co-culture model was successfully used to evaluate
intestinal permeability of insulin.
Recent microfluidic human intestine chip models have been de-
scribed where human intestinal cells, capillary endothelium, immune
cells and commensal gut microbiome grow, coexist and interact under
conditions of constant flow representative of peristalsis (Bein et al.,
2018). While early studies were done using Caco-2 cells, a primary
human small intestine-on-a-chip has been established using human
enteroids from patient duodenal biopsies (Kasendra et al., 2018). The
epithelial cells were grown on a porous membrane within the device
with human intestinal microvascular endothelius cultured in a parallel
channel. The use of primary cells provides the opportunity to use the
patients own cells and allow personalised therapies to be developed.
Human gut-on-a-chip microfluidic devices have been used to study in-
testinal pathophysiology and mechanisms of disease. For example, such
a device was used to investigate the interplay of the gut microbiome
and suppression of peristalsis on inflammation like that seen with IBD
(Kim et al., 2016), and similar devices have been suggested to in-
vestigate colorectal cancer (Pereira et al., 2016).
This chip microfluidic technology has also been used to establish a
multi-organ arrangement allowing cross talk between different tissues.
One multi-organ model, comprised of liver cells (hepatocytes and
Kupffer cells) integrated with intestinal cells (enterocytes, goblet cells
and dendritic cells). Using a range of biomarkers, gut-liver cross-talk
which is essential for normal physiology was established and the model
was used to study liver-gut inflammatory interactions (W.L.K. Chen
et al., 2017), and to investigate pharmacokinetic parameters including
intestinal drug permeability and hepatic metabolism relevant following
oral administration (Tsamandouras et al., 2017).
The microfluidic-chip technology, particularly the intestinal models
with capacity to reflect disease conditions, maybe a very powerful in
vitro tool to assess intestinal gene therapeutics.
4.2. Animal models
A variety of animal models including ex vivo, where tissues are
removed from the animal, in situ, where the animal has been surgically
manipulated and in vivo animal models, both healthy and diseased,
have been used to evaluate intestinal delivery of gene therapeutics
(Cryan and O'Driscoll, 2003; Guo et al., 2016; McCarthy et al., 2013;
O'Neill et al., 2011a). The majority of these studies have been per-
formed in rodents (mice and rats). A recent review on the ability of the
pig model to predict oral bioavailability in man (Henze et al., 2019) has
shown that while similarities in terms of GIT anatomy and physiology
exist species differences in individual drug metabolism have also been
suggested. The correlation between human and pig bioavailability, for a
limited bank of drugs, was comparable to that achieved between human
and dog. Consequently, the pig model may be a worthwhile model for
future studies with nucleic acid therapeutics.
4.3. Disease models
IBD are very complex diseases (Walsh et al., 2013) and it is difficult
to get a pre-clinical model which truly represents the complexity. Over
50 experimental colitis models (mice and rats) have been described,
they can be generally classified as; chemically induced, resulting from
genetic manipulation or those dependent on transfer of cells from do-
nors to immunodeficient recipients (Jiminez et al., 2015; Kiesler et al.,
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2015; O'Neill et al., 2011a). In the studies reviewed above (Section 3.2),
the most common model used involves induction of inflammation by
chemical means, e.g. by administration of dextran sodium sulphate
(DSS) in the drinking water which leads to disruption of the epithelium.
Other agents used include rectal administration of trinitrobenzene
sulfonic acid, which renders colonic proteins immunogenic to the host
immune system thereby driving a mucosal immune response that in-
itiates colitis (Kiesler et al., 2015). Administration of LPD has also been
used to stimulate development of inflammation and this model was
used by Aouadi et al. (2009) to assess the therapeutic value of GeRPs
containing siRNA following oral administration. Genetically manipu-
lated animals have also been used including the IL-10 knockout mouse
(Kühn et al., 1993). These animals develop inflammation of the colon
characterized by the existence of an inflammatory infiltrate composed
of lymphocytes, macrophages and neutrophils. Finally, adaptive
transfer colitis, involves the transfer of naïve CD4+ T cells
(CD4+CD45RBhigh T cells) from donor mice to immunodeficient
SCID or Rag1−/− recipient mice. This model was used by Xiao et al.
(2014), to investigate the efficacy of an antibody targeted NP loaded
with siRNA to alleviate colitis.
To achieve maximum efficacy from nucleic acid-based therapeutics
it is essential to identify a suitable gene target which can be a challenge
given the complex pathology of the disease. In the studies reviewed
above (Section 3.2) the most common targets for gene silencing were
TNF-alpha, IL-6, cyclin D1 and Map4k4 (Guo et al., 2016; Walsh et al.,
2013). The success of treatments is frequently assessed by monitoring
clinical signs of the disease such as changes in body weight, stool
consistency and rectal bleeding. In addition, markers of the disease
including colon length and weight, markers of inflammation for ex-
ample proinflammatory cytokines, colon histology and myeloperox-
idase activity have also been utilized (McCarthy et al., 2013; O'Neill
et al., 2011a).
Colorectal cancer (CRC) a variety of models has been described
(DE-Souza and Costa-Casagrande, 2018; Johnson and Fleet, 2013) but
most can be classified as chemically/environmentally induced, cancers
caused by genetic manipulation, or by injecting cancer cells locally
including subcutaneous xenografts or systemically to produce ortho-
topic tumors (Han et al., 2014; Kang et al., 2017). The chemical car-
cinogenic agents used include 1,2-dimethylhydrazine (DMH) and
azoxymethane (AOM) which is an active metabolite of DMH. Both are
reported to initiate tumors by a mechanism similar to that which occurs
naturally in humans (Perše and Cerar, 2011).
Due to the increasing level of knowledge re the genetic basis of CRC
numerous genetically modified animal models exist. The most com-
monly used models are based on mutations in the APC gene, p53 and K-
ras, the advantages and disadvantages of these models has previously
been reviewed (DE-Souza and Costa-Casagrande, 2018).
4.4. In silico
Physiologically based pharmacokinetic (PBPK) models utilise a
blend of in vitro pre-clinical data, including the physicochemical
properties of drugs, together with physiological conditions to predict in
vivo bioavailability for example following oral drug administration
(Kostewicz et al., 2014). There are several software packages com-
mercially available including GastroPlus 8.0, Simcyp 13.3 and GI-Sim
4.1, generally these are used to predict absorption of small molecular
weight drugs (Sjögren et al., 2016). Application of these modelling
packages to macromolecules such as nucleic acids is challenging due to
the physicochemical properties and the potential for degradation in the
lumen and in the gut wall. In addition, basic data used to produce
predict performance in man including permeability data is not readily
available. With the exception of a study on patients following bariatric
surgery (Darwich et al., 2012; Darwich et al., 2013; Sjögren et al.,
2016) no other PBPK model exists for patients with GI disease. Potential
exist to combine data generated using disease-specific biorelevant
media with PBPK models to evaluate the performance of orally ad-
ministered gene therapeutics (Effinger et al., 2018a; Otsuka et al.,
2013).
All animal models have advantages and disadvantages. It is im-
portant particularly in disease-based models to understand the limita-
tions of the model in terms of replicating the human condition. The
choice of a suitable model can often depend on the aims of the study
and this is worth considering when designing the experimental pro-
tocol. The field of oral administration of nucleic acid therapeutics is still
in its infancy and more work is needed to establish in vitro in vivo
correlations and to help build confidence in particular models to ac-
curately predict responses in man.
5. Outstanding barriers to translation
A series of outstanding barriers need to be overcome for the trans-
lation of nucleic acid-based therapeutics to oral drug products. The first
barrier is related to chemistry, manufacturing and controls (CMC) of the
advanced drug delivery systems to comply with the current good
manufacturing practices (cGMP) (Jeevanandam et al., 2016; Tyagi and
Santos, 2018) and the cost associated with the development and man-
ufacturing of these systems. The second barrier is linked with the
clinical challenges due to the poor translation of positive results ob-
served in preclinical models into human (Jeong et al., 2016; Tyagi and
Santos, 2018) and the specific health authorities' questions on phar-
macokinetics (PK), pharmacodynamics (PD) and in vivo targeting effi-
ciency to avoid off-target effects (Acharya et al., 2017).
5.1. Chemistry, manufacturing and control
The advanced drug delivery systems (DDS) needed to unlock the
therapeutic efficiency of nucleic acid-based drugs should comply with
the cGMP and ICH quality guidelines (e.g. ICH Q8(R2), (International
Conference of Harmonisation, 2009)) as any drug products. These
guidelines emphasize the need to identify the critical quality attributes
(CQA) of the drug product in relation with its biological activity. This is
needed to ascertain quality, safety and efficacy of drug products and
ensure batch-to-batch reproducibility.
The chemistry of materials used in the advanced DDS and their
critical material attributes (CMA) on the drug product properties should
be identified. For materials possessing a compendial monograph and
precedence of use in marketed drug product (e.g. Inactive Ingredient
Database (IID) listing, (U.S. Food and Drug Administration, 2018)), the
filing process is easier than for new materials. Most of the materials
used in the preparation of the advanced DDS described in this manu-
script: SEDDS, liposomes and nanoparticles are already listed in Phar-
macopeial monographs and used in drug products by either oral route
or injection. The exception would be for transfection agent like Lipo-
fectin or cationic polymers like polyethyleneimine or thiolated chit-
osans that do not have yet compendial monograph or precedence of use
in drug products. These new materials are essential for the performance
of nucleic acid-based therapeutics but will be considered as new che-
mical entities by national authorities and the translation of these mo-
lecules to the market will be very costly as safety of these materials
should be investigated as for any new molecules.
The manufacturing process used for the preparation of advanced
DDS should be described and critical process parameters (CPP) should
be identified to ascertain the control of the manufacturing process at
different scales and overtime. For SEDDS the manufacturing process is
quite simple as it consists of the mixing of materials to obtain an iso-
tropic solution of drug substance, surfactants, oils and solvent and then
the encapsulation of the solution in capsules. This process is already
widely used by the Pharmaceutical industry to manufacture SEDDS of
poorly water-soluble drugs as well as peptides (e.g. Cyclosporine A). A
market research analysis with PharmaCircle performed on April 19th,
2018 has allowed the identification of 150 marketed oral drug products
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worldwide with the drug delivery keyword ‘Lipid & SEDDS’. A vast
majority of these products are (or were) marketed in highly regulated
countries (108 are marketed in the USA for example) showing that
these formulations classically encapsulated in soft gelatin capsules
(73%) or hard capsules (23%) do comply to cGMP. The excipients'
composition of 86 drug products was available in the database to
classify these formulations according to the Lipid Formulation
Classification System (LFCS, (Pouton, 2006)). One quarter of these
formulations can clearly be identified as SEDDS – also referred as LFCS
Type II or Type III – with the use of self-emulsifying excipients, and the
rest of these formulations are mostly lipid solutions - LFCS Type I. The
fact that SEDDS are already marketed worldwide in oral drug products
is a major advantage for the seamless clinical translation of nucleic
acid-based therapeutics at a minimal cost. In addition, these capsule
formulations are generally stable in standard conditions for at least
three years.
Manufacturing process and scale-up of nano DDS like liposomes and
nanoparticles on FDA cGMPs in large scale production are more diffi-
cult and costlier (Jeevanandam et al., 2016) than classic tablet or
capsule manufacturing processes. This may be a reason why the Phar-
maCircle market analysis with the keyword ‘Liposome’ for oral mar-
keted drug products has reported only one reference. This is a product
named SiderAl Forte marketed in Italy by BMG Pharma S.r.l. However,
several marketed references of liposomes are available by injection and
prove that the manufacturing and scale-up of this type of formulation is
achievable even in sterile conditions.
Finally, the market analysis with the keywords ‘Nanoparticles’,
‘Polymeric nanoparticles’, ‘Lipid nanoparticles’ has resulted with no
marketed oral drug product. Lipid nanoparticle (LNP, Cullis and Hope,
2017) is scalable as one product has recently been approved by the US
FDA: LNP TTR-siRNA drug (Patisiran). Alike for liposome, lipid nano-
particles are already used in nucleic acid-based nanotherapeutics by
injection. These LNPs are stable at least one year at 4 °C. Overall, one
advantage for oral delivery of nucleic acid-based therapeutics versus
injection is that the sterilization step is not needed and would decrease
significantly the cost of goods.
The physicochemical characterization of advanced DDS is needed to
link the biological activity of the nucleic acid-based therapeutics with
the properties of the formulation. The nanoformulations are char-
acterized by their size distribution (mean, polydispersity index), mor-
phology and texture, their charge, surface chemistry and ability to re-
tain the drug substance in the nanocarrier along the GIT. In the case of
liposomes and nanoparticles, these properties are achieved after the
manufacturing process and should be characterized to ascertain the
control of the manufacturing process. However, for SEDDS that are
isotropic solutions of drug substance and excipients the nanodroplets or
micelles are only formed in situ after the ingestion of the formulation.
Appropriate and biorelevant characterization methods should be im-
plemented to verify the self-emulsification of the formulation and the
obtention of specific phases that allow maintaining the drug in colloids
(Jannin et al., 2015).
5.2. Clinical challenges and associated regulatory hurdles
No clinical trial for oral dosing of siRNA and pDNA were reported
on clinicaltrials.gov on January 1st, 2019. However, many clinical
studies where the nucleic acid-based therapeutics are dosed by injection
or surgery are reported. Within the 239 studies listed for pDNA and 60
for siRNA, some advanced DDS described in this manuscript for oral
dosing were tested in clinical trials by injection. Lipid nanoparticles
were the most common DDS used by intravenous administration for the
delivery of siRNA.
The clinical challenge of nucleic acid-based therapeutics is due to
the inability of most in vitro models and preclinical models to mimic
human with specific disease conditions (see Sections 4.1 and 4.2).
The next barrier to clinical translation is the PK, PD, toxicology and
biocompatibility of nucleic acid-based therapeutics (Acharya et al.,
2017). Nucleic acid-based therapeutics possess inherent poor pharma-
cokinetic properties (short biological half-life, poor penetration, and
non-specific stimulation of the immune system) and need to be deliv-
ered orally with a potent targeted DDS. Hence the final major reg-
ulatory hurdle for clinical translation is the in vivo targeting efficiency
of the DDS (Jeong et al., 2016) in order to avoid off-target silencing for
example with siRNA (Acharya et al., 2017). Advanced DDS such as LNP
are of prime importance (Granot and Peer, 2017) to allow accumulating
nucleic acid-based therapeutics in targeted organs and thus inducing a
therapeutic effect at a dose with an economically acceptable cost. These
DDS should minimize the suppression of genes other than the targeted
genes and the immune stimulation.
Finally, the approval of Patisiran - the first nucleic acid-based
therapeutics will pave the way for further and streamlined drug de-
velopment. It will give to the industry a clear roadmap of what FDA
requires in clinical development to ascertain the control of the targeted
nucleic acid-based therapeutics.
6. Conclusions and future prospects
Nucleic acids administered by the oral route must overcome phy-
sicochemical and physiological barriers. In particular, nucleases present
in the intestinal lumen and in intestinal cells cause the degradation of
RNA and pDNA. Their high molecular weight and high negative charge
make the crossing of the mucus layer and cell membrane difficult.
Therefore, formulation strategies have been developed to overcome this
enzymatic barrier and to enhance the nucleic acid absorption across the
intestinal barrier. Nevertheless, even with these optimized formula-
tions, the overall systemic bioavailability of nucleic acid remains very
low. Hence, the oral delivery of nucleic acid is mainly intended for their
local administration rather than for their systemic use. The most ob-
vious and most investigated biomedical applications are IBD and to a
lesser extend colorectal cancer. Many preclinical studies tend to in-
dicate that local delivery of formulated RNA could be translated to
clinical use. However, no clinical studies confirm the potential of orally
delivered nucleic acid-based therapeutics.
The future trends for the oral delivery of nucleic acid-based ther-
apeutics will rely on the future developments in molecular biology and
new knowledges in disease physiopathology to identify new targets for
gene therapy e.g. the identification of new genes involved in IBD.
Moreover, better formulations adapted both to protect the nucleic acid
from degradation and enhance its cellular permeation as well as to de-
liver it to the target site in the gastrointestinal tract will be required.
Multicomponent systems composed of a nucleic acid delivery system
such as nanoparticulate systems and a more conventional part for oral
delivery need to be optimized. In particular, based on their easy and
controlled formulation and manufacture, their well-characterized phar-
maceutical properties and the approval of most excipients by regulatory
agencies, SEDDS could potentially be promising for the oral delivery of
nucleic acid and require further preclinical and clinical studies.
In conclusion, it is difficult at this stage to provide a clear timeline
for clinical translation of oral nucleic acid therapeutics as many for-
mulation and regulatory barriers remain outstanding, however existing
pre-clinical data look convincing and particularly promising for local
delivery.
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